interleukin-12 modulators (Ligand)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameinterleukin-12 modulators (Ligand)
Drug Alias NameIL-12 modulators (Ligand)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionJanus kinase inhibitorsInterleukin-12 modulators
TargetsInterleukin-12Janus kinase
Therapy Area/IndicationsRejection of organ transplantationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLigand Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLigand Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A